



For immediate distribution
Source: DIAGNOS Inc.

2015.05.19

DARC Chooses CARA for a Clinical Trial in Conjunction with a Top Five Pharmaceutical Company in the United States

Brossard, Quebec, Canada – May 19, 2015 - Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today an agreement with Digital Angiography Reading Center (DARC).

DARC, a retina image analysis center located in New York, has signed a deal with a large U.S. pharmaceutical company for a clinical trial focusing on retina screening using tele-ophthalmology. For this trial, DIAGNOS will be providing its proprietary telemedicine platform, CARA, as well as all screening equipment and training.

“We are excited to continue to validate the tremendous value that CARA and other DIAGNOS services offer via projects like these. We have worked with DARC in the past and appreciate that they have chosen DIAGNOS to participate with them in this clinical trial,” said André Larente, Diagnos’ President.

There are millions of diabetic and pre-diabetic patients in the United States who do not routinely have their eyes screened for vision problems associated with diabetes¹. Diabetic retinopathy screening can make a major contribution towards improving their quality of life by identifying patients with unknown eye disorders and referring them for appropriate medical follow up².

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

About DIAGNOS Healthcare

DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

¹ Owsley, Cynthia, Gerald McGwin, Jr., David J. Lee, and Byron L. Lam. "Diabetes Eye Screening in Urban Settings Serving Minority Populations Detection of Diabetic Retinopathy and Other Ocular Findings Using Telemedicine." *JAMA Ophthalmology* 133.2 (2015): 174-81.

² Schwartz, Shulamit, Mariana Harasawa, Valeria Baldivieso, and Allison L. Sabel. "Nonmydriatic Fundus Camera for Diabetic Retinopathy Screening in a Safety Net Hospital: Effectiveness, Prevalence, and Risk Factors." *European Journal of Ophthalmology* 25.2 (2015): 145-52.



For immediate distribution
Source: DIAGNOS Inc.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com or contact:

André Larente, President, DIAGNOS Inc.
Tel. : [\(450\) 678-8882 ext 224](tel:(450)678-8882)